<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6704">
  <stage>Registered</stage>
  <submitdate>15/08/2017</submitdate>
  <approvaldate>15/08/2017</approvaldate>
  <nctid>NCT03251339</nctid>
  <trial_identification>
    <studytitle>Safety and Immunogenicity of MSB11455 in Healthy Subjects</studytitle>
    <scientifictitle>A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and NeulastaÂ® in Healthy Adult Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EMR200621-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MSB11455
Treatment: drugs - Neulasta

Experimental: MSB11455 - 

Experimental: Neulasta - 


Treatment: drugs: MSB11455
Subjects will receive single subcutaneous administration of MSB11455 on Day 1 of Period 1 and Period 2.

Treatment: drugs: Neulasta
Subjects will receive single subcutaneous administration of Neulasta on Day 1 of Period 1 and Period 2.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To Assess the Immunogenicity of MSB11455 Compared to Neulasta - Immunogenicity assessment will be based on Antidrug Antibody (ADA) response and development of Neutralizing Antibodies (NAB)</outcome>
      <timepoint>From first dose up to end of study (Up to 3 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety Profile as Assessed by Clinical Adverse events (AEs), Laboratory Variables, Vital Signs, Incidence of Antidrug Antibodies (ADAs), Neutralizing Antibodies(NABs) - Safety assessment will be based on number of subjects with AEs, abnormal laboratory variables, abnormal vital signs, incidence of ADAs and NABs</outcome>
      <timepoint>Day 1 up to a maximum of 1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects who provide signed and dated written informed consent.

          -  Subjects with laboratory test results within predefined ranges.

          -  Other protocol defined inclusion criteria could apply.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Subjects with known hypersensitivity to any component of Neulasta or MSB11455.

          -  Other protocol defined exclusion criteria could apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>21/08/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>404</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/09/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Merck KGaA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to compare the immunogenicity and safety of MSB11455 and
      Neulasta in healthy adult subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03251339</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Responsible</name>
      <address>Merck KGaA</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Merck KGaA Communication Center</name>
      <address />
      <phone>+496151725200</phone>
      <fax />
      <email>service@merckgroup.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>